谷氨酸羧肽酶Ⅱ
前列腺癌
放射性配体
癌症研究
化学
前列腺
计算生物学
癌症
医学
内科学
生物化学
受体
生物
作者
Susanne Lütje,Roger Slavik,Wolfgang P. Fendler,Ken Herrmann,Matthias Eiber
出处
期刊:Methods
[Elsevier]
日期:2017-06-27
卷期号:130: 42-50
被引量:45
标识
DOI:10.1016/j.ymeth.2017.06.026
摘要
Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as 68Ga or 18F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with 131I or 177Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI